Synthesis of (+)- and (-)-nojirimycin and their 1-deoxy derivatives from myo-inositol

Recent advances in the total synthesis of polyhydroxylated alkaloids via chiral oxazines

This review summarizes recently established methodologies developed for the enantioselective and diastereoselective synthesis of chiral 1,3-oxazines. These compounds are of interest as advanced synthetic intermediates in the total synthesis of structurally complex and biologically active polyhydroxylated alkaloids such as (+)-1-deoxynojirimycin, (-)-anisomycin, (+)-castanospermine, (+)-casuarine, (-)-conduramine F-1, (-)-sphingofungin B, Neu5Ac methyl ester, and other natural products. The devised synthetic approach aims to offer a direct, efficient, and adaptable method for obtaining both pure enantiomers and pure diastereomers. It revolves around utilizing chiral building blocks like syn,syn-, syn,syn,anti-, syn,anti-, syn,anti,syn-, anti,syn-, anti,syn,syn-, and anti,syn,anti-oxazines. By integrating oxazine chemistry with established and innovative transformations, this approach enabled the synthesis of 30 polyhydroxylated amines across various studies conducted between 2007 and 2022.

N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease

The highly stereocontrolled de novo synthesis of l-NBDNJ (the unnatural enantiomer of the iminosugar drug Miglustat) and a preliminary evaluation of its chaperoning potential are herein reported. l-NBDNJ is able to enhance lysosomal α-glucosidase levels in Pompe disease fibroblasts, either when administered singularly or when coincubated with the recombinant human α-glucosidase. In addition, differently from its d-enantiomer, l-NBDNJ does not act as a glycosidase inhibitor.

Total syntheses and structural validation of lincitol A, lincitol B, uvacalol I, uvacalol J, and uvacalol K

First total syntheses of lincitol A, lincitol B, uvacalol I, uvacalol J and uvacalol K were achieved in racemic form, validating their structure from a common intermediate, which was synthesized in six steps from low-cost and extensively available myo-inositol.

Synthesis and evaluation of amino-threoses in d- and l-series: Are five membered ring amino-sugars more potent glycosidase inhibitors than the six membered ones?

Cyclic D- and L-4-aminothreose were synthesised from ethyl D- and L-tartrate, respectively. D-aminothreose was a potent inhibitor of alpha-glucosidase and of alpha-mannosidase. From the glycosidase inhibition potencies of the four 4-amino-4-deoxy-tetroses, the contribution of binding of each functionality of the 5 and 6 membered ring amino-sugars towards the various glycosidases is discussed.

Polyhydroxylated homoazepanes and 1-deoxy-homonojirimycin analogues: Synthesis and glycosidase inhibition study

The Johnson-Claisen rearrangement of D-gluco and L-ido-derived allylic orthoesters afforded gamma,delta-unsaturated ester that on ester reduction, epoxidation, regioselective oxirane opening by sodium azide and hydrogenation led to sugar amino alcohols--immediate precursors for 1-deoxy-homonojirimycin 3a,b, and polyhydroxylated homoazepanes 4a,b. Our synthetic approach and glycosidase inhibitory activity is reported.

Synthesis of radioiodinated 1-deoxy-nojirimycin derivatives: novel glucose analogs

Novel lipophilic and neutral glucose analogs, which are potentially useful for tumor imaging, have been developed. They are designed to circumvent Glut-facilitated transport mechanism, and direct the localization by either hexokinase binding or enzyme reactions (phosphorylation) as potential metabolic markers of tumor cells. Syntheses of tetraacetylated N-(3'-iodo-2'-propenyl)-1-deoxy-nojirimycin (11) and N-(3'-iodo-benzyl)-1-deoxy-nojirimycin (14) were achieved by reacting 1-deoxy-nojirimycin with appropriate alkylating agents. The corresponding tri-butyltin derivatives were also prepared as the starting materials for preparation of I-125-labeled compounds for biodistribution study in rats. Biodistribution in rats showed that [123I]14 exhibited a modest initial brain uptake and retention at a later time (0.59, 0.38, 0.30, and 0.30% dose/organ at 2, 30, 60, and 120 min after an intravenous [i.v.] injection, respectively), whereas [125I]11 displayed a lower brain uptake (0.35, 0.27, 0.20, and 0.18% dose/organ at 2, 30, 60, and 120 min). In addition, compounds with free hydroxyl groups (12 and 13) were also obtained. As expected, after an i.v. injection, these free hydroxyl compounds showed a dramatic decrease in brain uptake in rats. It appears that both of the acetylated agents (11 and 14), which display higher lipophilicity (partition coefficient [P.C.] = 57.9 and 1,462, respectively), can penetrate the blood-brain barrier (BBB) by a simple diffusion mechanism whereas the free hydroxy compounds (12 and 13), with lower lipophilicity (P.C. = 0.43 and 6.8), showed no brain uptake. A similar pair of glucose derivatives, fluorodeoxyglucose (FDG) and tetraacetylated FDG (AFDG), displayed a dramatic difference in brain uptake in rats. While the lipophilic AFDG (P.C. = 3.79) may penetrate the intact BBB, due to its relatively low P.C. value, the first pass extraction due to simple diffusion mechanism may be low (brain uptake at 2 min was 0.68% dose/organ). The FDG itself has a very low lipophilicity (P.C. = 0.22) but it can be taken up into the brain by a glucose transporter mediated mechanism to cross the BBB (brain uptake at 2 min was 2.53% dose/organ). Preliminary data of these glucose derivatives suggest that further studies are needed to elucidate the uptake and retention mechanisms and their potential application as tumor imaging agents.